NICOYA年衍药业
/

PRODUCTS

Our products.

Explore NICOYA products, regional progress and partnerships.

OUR PIPELINE

Our pipeline

In-house and in-licensed programs focused on kidney disease.

OriginProgramResearch area / IndicationTerritoryPositioning and market potentialPreclinicalINDPhase I / IIPhase IIINDA / BLA
In-house R&DNT-003IgA nephropathy, FSGSGlobal

Dual-target inhibitor with high technical complexity

Market potential above 1 billion
PCC
NT-004Diabetic kidney disease, hypertension and other indicationsGlobal

Differentiated established target with limited competition; potential for breakthrough therapy in selected diseases

Market potential above 1 billion
Phase I
NT-007Diabetic kidney disease and other indicationsGlobal

Dual antagonist with first-in-class potential

Billion-scale market potential
IND preparation
In-licensedNT-002 · RAYALDEECKD-related vitamin D deficiency and secondary hyperparathyroidismGreater China

A first-in-class product with high technical barriers, addressing unmet needs

Billion-scale market potential
Approved overseas; mainland China registration progressingMacao approval in November 2024; China phase III completed and pre-NDA dialogue submitted in April 2025; mainland China approval expected around 2026

Preclinical · IND · Phase I / II · Phase III · NDA / BLA

NT-003

In-house R&D
Research area / Indication
IgA nephropathy, FSGS
Territory
Global
Positioning
Dual-target inhibitor with high technical complexity
Market potential
Market potential above 1 billion
PCC

NT-004

In-house R&D
Research area / Indication
Diabetic kidney disease, hypertension and other indications
Territory
Global
Positioning
Differentiated established target with limited competition; potential for breakthrough therapy in selected diseases
Market potential
Market potential above 1 billion
Phase I

NT-007

In-house R&D
Research area / Indication
Diabetic kidney disease and other indications
Territory
Global
Positioning
Dual antagonist with first-in-class potential
Market potential
Billion-scale market potential
IND preparation

NT-002 · RAYALDEE

In-licensed
Research area / Indication
CKD-related vitamin D deficiency and secondary hyperparathyroidism
Territory
Greater China
Positioning
A first-in-class product with high technical barriers, addressing unmet needs
Market potential
Billion-scale market potential
Approved overseas; mainland China registration progressing

Macao approval in November 2024; China phase III completed and pre-NDA dialogue submitted in April 2025; mainland China approval expected around 2026

Unmet needs in nephrology guide a portfolio spanning early research, clinical development and registration.

Research indications are not approved indications. Market potential and registration targets are forward-looking, not guarantees of performance, clinical success or approval. Partnership interests are distinct from active development.

Find product labeling, regional information and guidance on using website materials.